Imagine conquering childhood cancer, only to find out that years down the road your heart may fail. Unfortunately, many children who have battled cancer face this reality. While often lifesaving, the ...

Despite improved outcomes in newly diagnosed pediatric AML, relapsed disease remains a therapeutic challenge. Factors contributing to slow progress in improving outcomes include inherent challenges in ...

Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation Purpose: To evaluate the ...

Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are the most common pediatric cancers and among the leading causes of death in children. To improve kids' chances of survival, early ...

Panelists emphasize that the approval of menin inhibitors has transformed the treatment landscape for KMT2A-rearranged acute myeloid leukemia (AML) by replacing historically limited and toxic ...

FDA recommends inclusion of patients as young as 6 months – younger than Moleculin had proposed – to be allowed in the pediatric clinical study Enrollment and dosing are ongoing in pivotal, adaptive ...

The chemotherapy treatments necessary to treat Acute Myeloid Leukemia (AML) in children can be grueling on the body, and can cause health-related complications during therapy, as well as long down the ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood ...

They are Kristensen and colleagues’ 1996 paper on cancer morbidity in the children of agricultural workers in Norway, and an unpublished extension of the Meinert et al. (2000) case-control interview ...

An East Yorkshire family has turned heartbreak into hope by funding research into childhood cancer in memory of their son.